{"id":54405,"date":"2026-01-16T20:01:06","date_gmt":"2026-01-16T12:01:06","guid":{"rendered":"https:\/\/flcube.com\/?p=54405"},"modified":"2026-01-16T20:01:07","modified_gmt":"2026-01-16T12:01:07","slug":"signet-therapeutics-completes-preclinical-study-for-sigx2649-pan-tead-inhibitor-for-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54405","title":{"rendered":"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors"},"content":{"rendered":"\n<p><strong>Signet Therapeutics<\/strong>, incubated by <strong>Xtalpi Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2228:HKG\">HKG: 2228<\/a>), announced completion of preclinical studies for <strong>SIGX2649<\/strong>, a <strong>pan\u2011TEAD inhibitor<\/strong> developed using its <strong>&#8220;AI + organoid&#8221; platform<\/strong>. The company plans <strong>IND filings<\/strong> with regulatory authorities in <strong>China and the United States<\/strong> for this potential <strong>first\u2011in\u2011class and best\u2011in\u2011class<\/strong> solid tumor therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>Pan\u2011TEAD inhibitor<\/strong> blocking all four TEAD transcription factor subtypes (TEAD1\u20114)<\/li>\n\n\n\n<li><strong>Dual Blockade Mechanism:<\/strong> Inhibits TEAD activity while promoting binding of <strong>transcriptional repressor VGLL4<\/strong> to TEAD, achieving synergistic transcriptional repression<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Discovered via <strong>XtalPi\u2019s AI + organoid platform<\/strong>, integrating computational drug design with human\u2011derived tumor models<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>First TEAD inhibitor<\/strong> to demonstrate <strong>dual blockade<\/strong> and <strong>AI\u2011driven discovery<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-data-highlights\">Preclinical Data Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>SIGX2649<\/th><th>Competitor TEAD Inhibitors<\/th><th>Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>TEAD Subtype Inhibition<\/strong><\/td><td>All 4 subtypes<\/td><td>Partial\/Selective<\/td><td><strong>Broader coverage<\/strong><\/td><\/tr><tr><td><strong>Anti\u2011tumor Activity<\/strong><\/td><td>Strong<\/td><td>Moderate<\/td><td><strong>Superior potency<\/strong><\/td><\/tr><tr><td><strong>Kidney Toxicity<\/strong><\/td><td>Significantly lower<\/td><td>High<\/td><td><strong>Improved safety<\/strong><\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>TEAD blockade + VGLL4 promotion<\/td><td>TEAD blockade only<\/td><td><strong>Dual blockade<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Demonstrated <strong>robust tumor growth inhibition<\/strong> across multiple solid tumor organoid models (colorectal, pancreatic, lung)<\/li>\n\n\n\n<li><strong>Safety:<\/strong> <strong>Minimal off\u2011target effects<\/strong> and <strong>significantly reduced kidney accumulation<\/strong> vs. other TEAD inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Solid Tumor Incidence (2026E)<\/strong><\/td><td>4.2\u202fmillion<\/td><td>18.5\u202fmillion<\/td><\/tr><tr><td><strong>TEAD\u2011Driven Tumors (Hippo pathway)<\/strong><\/td><td>1.5\u202fmillion<\/td><td>6.5\u202fmillion<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>\u00a528\u202fbillion<\/td><td>$18\u202fbillion<\/td><\/tr><tr><td><strong>TEAD Inhibitor Penetration<\/strong><\/td><td>0\u202f%<\/td><td>0\u202f%<\/td><\/tr><tr><td><strong>SIGX2649 Peak Revenue (2032E)<\/strong><\/td><td>\u00a53.5\u202fbillion<\/td><td>$2.2\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vivace Therapeutics<\/strong> \u2013 VTX\u20111 (TEAD inhibitor, Phase\u202fI)<\/li>\n\n\n\n<li><strong>Ikena Oncology<\/strong> \u2013 IK\u2011930 (TEAD1 inhibitor, Phase\u202fI)<\/li>\n\n\n\n<li><strong>Signet\/XtalPi<\/strong> \u2013 <strong>SIGX2649<\/strong> \u2013 <strong>First pan\u2011TEAD inhibitor<\/strong> with <strong>dual blockade<\/strong> and <strong>AI\u2011driven discovery<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-next-steps\">Strategic Positioning &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IND Filings:<\/strong> Planned for <strong>Q2\u202f2026<\/strong> (China) and <strong>Q3\u202f2026<\/strong> (US)<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> Phase\u202fI study to evaluate safety, PK, and preliminary efficacy in <strong>TEAD\u2011positive solid tumors<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> XtalPi\u2019s <strong>robotic synthesis platform<\/strong> will enable rapid scale\u2011up for clinical supply<\/li>\n\n\n\n<li><strong>Pipeline Value:<\/strong> SIGX2649 is Signet\u2019s <strong>second pipeline<\/strong> after SIGX1098 (undisclosed target); validates <strong>AI + organoid platform<\/strong> for <strong>first\u2011in\u2011class oncology assets<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IND filing timelines, clinical development, and commercial projections for SIGX2649. Actual results may differ due to regulatory approval processes, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,90,1112,221,696],"class_list":["post-54405","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-filings","tag-hkg-2228","tag-signet-therapeutics","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649, a pan\u2011TEAD inhibitor developed using its &quot;AI + organoid&quot; platform. The company plans IND filings with regulatory authorities in China and the United States for this potential first\u2011in\u2011class and best\u2011in\u2011class solid tumor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54405\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649, a pan\u2011TEAD inhibitor developed using its &quot;AI + organoid&quot; platform. The company plans IND filings with regulatory authorities in China and the United States for this potential first\u2011in\u2011class and best\u2011in\u2011class solid tumor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54405\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T12:01:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-16T12:01:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54405#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54405\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors\",\"datePublished\":\"2026-01-16T12:01:06+00:00\",\"dateModified\":\"2026-01-16T12:01:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54405\"},\"wordCount\":372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial filings\",\"HKG: 2228\",\"Signet Therapeutics\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54405#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54405\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54405\",\"name\":\"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-16T12:01:06+00:00\",\"dateModified\":\"2026-01-16T12:01:07+00:00\",\"description\":\"Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649, a pan\u2011TEAD inhibitor developed using its \\\"AI + organoid\\\" platform. The company plans IND filings with regulatory authorities in China and the United States for this potential first\u2011in\u2011class and best\u2011in\u2011class solid tumor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54405#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54405\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54405#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649, a pan\u2011TEAD inhibitor developed using its \"AI + organoid\" platform. The company plans IND filings with regulatory authorities in China and the United States for this potential first\u2011in\u2011class and best\u2011in\u2011class solid tumor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54405","og_locale":"en_US","og_type":"article","og_title":"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors","og_description":"Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649, a pan\u2011TEAD inhibitor developed using its \"AI + organoid\" platform. The company plans IND filings with regulatory authorities in China and the United States for this potential first\u2011in\u2011class and best\u2011in\u2011class solid tumor therapy.","og_url":"https:\/\/flcube.com\/?p=54405","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-16T12:01:06+00:00","article_modified_time":"2026-01-16T12:01:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54405#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54405"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors","datePublished":"2026-01-16T12:01:06+00:00","dateModified":"2026-01-16T12:01:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54405"},"wordCount":372,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial filings","HKG: 2228","Signet Therapeutics","Xtalpi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54405#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54405","url":"https:\/\/flcube.com\/?p=54405","name":"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-16T12:01:06+00:00","dateModified":"2026-01-16T12:01:07+00:00","description":"Signet Therapeutics, incubated by Xtalpi Inc. (HKG: 2228), announced completion of preclinical studies for SIGX2649, a pan\u2011TEAD inhibitor developed using its \"AI + organoid\" platform. The company plans IND filings with regulatory authorities in China and the United States for this potential first\u2011in\u2011class and best\u2011in\u2011class solid tumor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54405#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54405"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54405#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan\u2011TEAD Inhibitor for Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54405"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54405\/revisions"}],"predecessor-version":[{"id":54406,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54405\/revisions\/54406"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}